A Serial Dilution Study of Gadolinium-Based MR Imaging Contrast Agents

References

1. ↵
   de Haen C. Conception of the first magnetic resonance imaging contrast agents: a brief history. Top Magn Reson Imaging 2001;12:221–30

   CrossRefPubMed
2. ↵
   Thomsen HS. European Society of Urogenital Radiology guidelines on contrast media application. Curr Opin Urol 2007;17:70–76

   CrossRefPubMedWeb of Science
3. Thomsen HS, Marckmann P, Logager VB. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis? Acta Radiol 2007;48:593–96

   CrossRefPubMedWeb of Science
4. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 2003;14:426–35

   CrossRefPubMed
5. ↵
   Duff G. Gadolinium-containing MRI contrast agents and nephrogenic systemic fibrosis (NSF): Update—Direct Healthcare Professional Communication. In: Co H, ed. Medicines. 2007; Available at: http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName=CON2030229&ssTargetNodeId=221
6. ↵
   de Haen C, Cabrini M, Akhnana L, et al. Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 1999;23 (suppl 1):S161–68

   CrossRefPubMed
7. ↵
   Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006;41:213–21

   CrossRefPubMed
8. ↵
   Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 1998;33:798–809

   CrossRefPubMed
9. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents. Invest Radiol 2006;41:222–28

   CrossRefPubMed
10. ↵
    Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006 2006;1:128–37

    CrossRefPubMed
11. ↵
    Colosimo C, Demaerel P, Tortori-Donati P, et al. Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children. Pediatr Radiol 2005;35:501–10. Epub 2005 Jan 28

    CrossRefPubMed
12. ↵
    Essig M, Lodemann KP, Le-Huu M, et al. Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T. Invest Radiol 2006;41:256–63

    CrossRefPubMed
13. Essig M, Tartaro A, Tartaglione T, et al. Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators. Acad Radiol 2006;13:744–51

    CrossRefPubMed
14. Kuhn MJ, Picozzi P, Maldjian JA, et al. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg 2007;106:557–66

    CrossRefPubMed
15. ↵
    Maravilla KR, Maldjian JA, Schmalfuss IM, et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 2006;240:389–400

    CrossRefPubMed
16. ↵
    Shellock FG, Parker JR, Pirovano G, et al. Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine. J Magn Reson Imaging 2006;24:1378–85

    CrossRefPubMed
17. ↵
    Gandhi SN, Brown MA, Wong JG, et al. MR contrast agents for liver imaging: what, when, how. Radiographics 2006;26:1621–36

    CrossRefPubMed
18. ↵
    Knopp MV, Giesel FL, Radeleff J, et al. Bile-tagged 3D magnetic resonance colonography after exclusive intravenous administration of gadobenate dimeglumine, a contrast agent with partial hepatobiliary excretion. Invest Radiol 2001;36:619–23

    CrossRefPubMed
19. ↵
    Lim JS, Kim MJ, Jung YY, et al. Gadobenate dimeglumine as an intrabiliary contrast agent: comparison with mangafodipir trisodium with respect to non-dilated biliary tree depiction. Korean J Radiol 2005;6:229–34

    PubMed
20. ↵
    McAuliffe MJ, Lalonde FM, McGarry D, et al. Medical Image Processing, Analysis, & Visualization in Clinical Research: Proceedings of the Fourteenth IEEE Symposium on Computer-Based Medical Systems, Bethesda, Md, 26–27 July 2001: IEEE Computer Society; Los Alamitos, CA;2001 :6
21. ↵
    Marckmann P, Skov L, Rossen K, et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007;22:3174–78. Epub 2007 May 4

    Abstract/FREE Full Text